Impact of Monitoring on Medical Device Vulnerabilities

This whitepaper examines how behavior monitoring and intrusion detection can reduce the likelihood and severity of cybersecurity vulnerabilities in connected medical devices.

By analyzing over 140 vulnerability advisories from the ICS-CERT database, the paper demonstrates that monitoring could have mitigated risk in 41.7% of all disclosures — often turning “uncontrolled” vulnerabilities into “controlled” ones under FDA postmarket criteria.

It also highlights how monitoring aligns with the FDA’s secure-by-design framework, showing that the ability to detect abnormal device behavior is now an essential capability for both manufacturers and healthcare delivery organizations (HDOs).

As the number of connected devices grows — now estimated at over 9 million in U.S. hospitals alone — the attack surface expands exponentially.

While FDA guidance requires manufacturers to design devices with security and monitoring in mind, implementation varies widely.

Device-based monitoring offers a scalable, proactive way to detect and respond to anomalies, reducing potential recalls, limiting postmarket exposure, and enabling continuous cybersecurity assurance across both clinical and home-use environment.

• Monitoring directly impacts vulnerability severity, with CVSS scores lowered in up to 42% of cases.
• FDA now expects embedded device monitoring as part of the secure-by-design lifecycle.
• Device-based monitoring is especially critical for remote and home-use medical devices.
• Monitoring supports both postmarket risk reduction and regulatory evidence generation.
• Combining device-level and HDO-level monitoring creates a layered defense that mitigates risk and reduces recall exposure.